Signifor FDA Approval History
FDA Approved: Yes (First approved December 14, 2012)
Brand name: Signifor
Generic name: pasireotide
Dosage form: Injection
Company: Novartis Pharmaceuticals Corporation
Treatment for: Cushing's Syndrome
Signifor (pasireotide) is a multireceptor targeting somatostatin analog for the treatment of patients with Cushing's disease.
Development timeline for Signifor
|Dec 14, 2012||Approval FDA Approves Signifor, a New Orphan Drug for Cushing’s Disease|
|Nov 7, 2012||Novartis drug Signifor recommended by FDA advisory committee for approval to treat patients with Cushing's disease|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.